EUVIMEDEUVIMED entdecken
Crossref

Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma

Beichuan Pang, Bangyou Zuo, Liang Huang, Xinyu You, Tao Liu, Jianjie Hao, Chengxiang Yuan, Chong Yang, Wan Yee Lau, Yu Zhang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Beichuan Pang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of Chi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Protein Kinase Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Local treatment may function synergistically with immunotherapy and targeted agents. This study aimed to assess the effectiveness and safety of transcatheter arterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and programmed death-1 (PD-1) inhibitors in patients with initially unresectable hepatocellular carcinoma (uHCC). METHODS: A retrospective study was conducted on patients diagnosed with initially uHCC who received combined treatment of TACE-HAIC combined with TKIs and PD-1 inhibitors from July 2020 to February 2023. The primary endpoints were overall survival (OS) and progression free survival (PFS) and adverse events (AEs). Objective response rate (ORR), disease control rate (DCR) and conversion surgery rate (CSR), whereas the secondary endpoints. RESULTS: After screening, a total of 62 patients were selected for this study. The overall median OS was 18.2 (95% CI 16.24-20.16) months and median PFS was 9.2 (95% CI 7.24-11.16) months. Based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria and RECIST v1.1 criteria, ORR was 67.7% (42/62), and the DCR was 90.3% (56/62), the CSR was 27.4% (17/62). The most common treatment-emergent adverse events (TEAEs) were transaminitis (56.4%, 35/62), nausea and vomiting (43.5%, 27/62), thrombocytopenia (37.1%, 23/62), abdominal pain (33.9%, 21/62), and fever (33.9%, 21/62). CONCLUSIONS: TKIs combined with PD-1 inhibitors plus TACE-HAIC therapy represents an effective and tolerable treatment option in patients with uHCC. Patients undergoing surgery after combination therapy may have survival benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticProtein Kinase InhibitorsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultProgrammed Cell Death 1 ReceptorTreatment OutcomeCombined Modality TherapyInfusions, Intra-ArterialAntineoplastic Combined Chemotherapy ProtocolsHepatic Artery

Stichwörter der Autor:innen

Conversion therapyHAICHepatocellular carcinomaSystemic treatmentTACE

Substanzen

Protein Kinase InhibitorsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
  • Department of Hepatobiliary Surgery, Sichuan Taikang Hospital, Chengdu, Sichuan, China.
  • Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong SAR, China.
  • Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. Electronic address: zhangyuqg@med.uestc.e…

Förderung

  • Science and Technology Department of Sichuan Province
  • National Natural Science Foundation of China

Zitieren

APA

Pang, B., Zuo, B., Huang, L., You, X., Liu, T., Hao, J., Yuan, C., Yang, C., Yee Lau, W., & Zhang, Y. (2024). Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112492

Vancouver

Pang B, Zuo B, Huang L, You X, Liu T, Hao J, et al. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112492

BibTeX
@article{Pang2024,
  author = {Pang, Beichuan and Zuo, Bangyou and Huang, Liang and You, Xinyu and Liu, Tao and Hao, Jianjie and Yuan, Chengxiang and Yang, Chong and Yee Lau, Wan and Zhang, Yu},
  title = {Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112492}
}
Kostenlos starten →